Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease.

Dysregulation at the intestinal epithelial barrier is a driver of inflammatory bowel disease (IBD). However, the molecular mechanisms of barrier failure are not well understood. Here, we demonstrate dysregulated mitochondrial fusion in intestinal epithelial cells (IECs) of patients with IBD and show that impaired fusion is sufficient to drive chronic intestinal inflammation.

Transcriptomic profiling of chronic hand eczema skin reveals shared immune pathways and molecular drivers across subtypes.

Background: Chronic hand eczema (CHE) is a common skin disease with different subtypes, but knowledge of the molecular patterns associated with each subtype is limited.

Objective: To characterize the CHE transcriptome across subtypes.

Methods: Using RNA-sequencing, we studied the transcriptome of 220 full-thickness skin biopsies collected from palms, dorsa, and arms from 96 patients with CHE and/or atopic dermatitis (AD) and 32 healthy controls.

Change Your Diet: How CO, Plant Phenology and Genotype Alter Grapevine Quality and Affect Performance and Larval Transcriptome of an Insect Herbivore.

Herbivorous insects need to cope with changing host plant biochemistry caused by abiotic and biotic impacts, to meet their dietary requirements. Larvae of the multivoltine European grapevine moth Lobesia botrana, one of the main insect pests in viticulture, feed on both flowers and berries. The nutritional value and defence compounds of these organs are changing with plant phenology and are affected by climate change which may accordingly alter plant-insect interactions.

Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: An analysis of the PRIMROSE 1 & 2 trials.

Objective: To study the timing of the effect of linzagolix, an oral GnRH antagonist, on significant reduction in heavy menstrual bleeding (HMB) in women with uterine fibroids.

Design: The study used pooled data from PRIMROSE1 and PRIMROSE2, two double-blind, similar placebo-controlled trials of linzagolix in US and Europe, respectively. Eligible participants were randomized equally across four treatment arms (linzagolix 100mg and 200mg, with and without concomitant hormonal add-back therapy [ABT] consisting of 1 mg estradiol and 0.